Regardless of the sequential decrease in Current Liabilities, during the second quarter 2026, Quick Ratio deteriorated to 3.97 below Alx Oncology Holdings Inc's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 206 other companies have achieved higher Quick Ratio than Alx Oncology Holdings Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 645, from total ranking in the first quarter 2026 at 1797.

Explain Quick Ratio?
How much Cash & cash equivalents ALXO�s has?
What are ALXO�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

ALXO Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	-69.59 %	7.66 %	32.72 %	-14.28 %	-50.98 %
Y / Y Cash & cash equivalent Change	-71.31 %	43.44 %	-64.94 %	-59.19 %	-49.39 %
Quick Ratio MRQ	3.97	6.95	1.82	2.19	4.21
ALXO's Total Ranking	# 645	# 1797	# 1488	# 1023	# 874
Seq. Current Liabilities Change	-71.6 %	-17.82 %	-11.43 %	47.08 %	0.57 %
Seq. Cash & cash equivalent Change	-83.79 %	213.29 %	-26.12 %	-23.56 %	-18.93 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 207
Healthcare Sector	# 348
Overall Market	# 934

Quick Ratio Statistics
High	Average	Low
69.99	14.55	1.68
(Dec 31 2020)		(Dec 31 2019)

Financial Statements
Alx Oncology Holdings Inc's Current Liabilities	$ 6 Millions	Visit ALXO's Balance sheet
Alx Oncology Holdings Inc's Cash & cash equivalent	$ 23 Millions	Visit ALXO's Balance sheet
Source of ALXO's Sales		Visit ALXO's Sales by Geography

Cumulative Alx Oncology Holdings Inc's Quick Ratio

ALXO's Quick Ratio for the trailling 12 Months

ALXO Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-11.59 %	-15.49 %	-26.05 %	-39.71 %	-37.65 %
Y / Y Cash & cash equivalent TTM Growth	-40.79 %	-38.77 %	-52.15 %	-43.37 %	-33.98 %
Quick Ratio TTM	3.43	3.56	3.14	4.36	5.13
Total Ranking TTM	# 1291	# 1626	# 1145	# 1311	# 1543
Seq. Current Liabilities TTM Growth	-14.37 %	1.6 %	7.22 %	-5.22 %	-18.14 %
Seq. Cash & cash equivalent TTM Growth	-17.4 %	15.04 %	-22.7 %	-19.39 %	-14.58 %

Quick ratio ranking by company, industry and sector >> Back to ALXO Financial Strength Comparisons >> Go to Compare ALXO Quick Ratio to its Competitors

News about Alx Oncology Holdings Inc Quick Ratio

ALX Oncology Advances Cancer Therapeutics Key Updates on Evorpacept from Major Clinical Trials

ALX Oncology Advances Cancer Therapeutics: Key Updates on Evorpacept from Major Clinical Trials SOUTH SAN FRANCISCO, Calif. In a promising development for oncology, ALX Oncology Holdings Inc. (Nasdaq: ALXO) has announced several significant updates regarding its lead therapeutic candidate, Evorpacept, which is being explored for its efficacy in treating various malignancies. The company, known for its innovative approach in harnessing the immune system to combat cancer, is at the forefront of groundbreaking clinical research, emphasizing the potential of Evorpacept in fighting HER2-positive gastric cancers and advanced breast cancers, among others.The most notable announcement pertains to the acceptance of updated results from the Phase 2 ASPEN-06 clinical trial for Evorpacept, set to be presented orally at the prestigious American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. This event, scheduled for January 23 - 25, 2025, in San Francisco, serves as a significant platform for leading oncologists and researchers to share cutting-edge findings in the realm of gastrointestinal oncology. Evorpacept, a highly differentiated CD47 blocker, has shown promise in the targeted treatment of HER2-positive gastric cancer, a notoriously aggressive form of cancer characterized by its challenging prognosis and limited therapeutic options.

On the trailing twelve months basis In spite of the year on year decrease in ALXO's Current Liabilities to $5.73 millions, cumulative Quick Ratio to 3.43 below the ALXO average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 435 other companies have achieved higher Quick Ratio than Alx Oncology Holdings Inc. While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 3001.

Explain Quick Ratio?
How much Cash & cash equivalents ALXO�s has?
What are ALXO�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 436
Healthcare Sector	# 892
Within the Market	# 645

trailing twelve months Quick Ratio Statistics
High	Average	Low
36.94	10.02	0.49
(Jun 30 2021)		(Sep 30 2024)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Xenon Pharmaceuticals Inc	10.85	$ 930.686 Millions	$ 85.795 Millions
Bicycle Therapeutics Plc	10.71	$ 510.052 Millions	$ 47.635 Millions
Entrada Therapeutics Inc	10.44	$ 223.112 Millions	$ 21.371 Millions
Vera Therapeutics Inc	10.33	$ 499.161 Millions	$ 48.321 Millions
Ideaya Biosciences Inc	10.03	$ 828.955 Millions	$ 82.677 Millions
Gri Bio Inc	9.95	$ 10.947 Millions	$ 1.100 Millions
Renovorx Inc	9.86	$ 18.579 Millions	$ 1.884 Millions
Savara Inc	9.83	$ 173.034 Millions	$ 17.599 Millions
Bullfrog Ai Holdings Inc	9.79	$ 6.918 Millions	$ 0.707 Millions
Enveric Biosciences Inc	9.63	$ 8.296 Millions	$ 0.861 Millions
Pliant Therapeutics Inc	9.62	$ 158.500 Millions	$ 16.484 Millions
Rezolute Inc	9.44	$ 107.801 Millions	$ 11.418 Millions
Crescent Biopharma Inc	9.26	$ 171.593 Millions	$ 18.537 Millions
Marker Therapeutics inc	9.10	$ 22.031 Millions	$ 2.420 Millions
Synlogic Inc	9.03	$ 13.200 Millions	$ 1.461 Millions
Spruce Biosciences Inc	8.78	$ 96.300 Millions	$ 10.963 Millions
Newamsterdam Pharma Company N v	8.69	$ 633.854 Millions	$ 72.974 Millions
Medicinova Inc	8.58	$ 25.416 Millions	$ 2.961 Millions
Lixte Biotechnology Holdings Inc	8.45	$ 12.670 Millions	$ 1.500 Millions
Atrium Therapeutics Inc	8.38	$ 264.135 Millions	$ 31.508 Millions
Cytomx Therapeutics Inc	8.29	$ 330.280 Millions	$ 39.861 Millions
Grace Therapeutics Inc	8.24	$ 13.756 Millions	$ 1.669 Millions
Talphera Inc	7.98	$ 33.410 Millions	$ 4.188 Millions
Rocket Pharmaceuticals Inc	7.79	$ 342.940 Millions	$ 44.031 Millions
Milestone Pharmaceuticals Inc	7.73	$ 171.481 Millions	$ 22.184 Millions
Nuvation Bio Inc	7.62	$ 660.956 Millions	$ 86.755 Millions
Ibio inc	7.50	$ 88.049 Millions	$ 11.745 Millions
Promis Neurosciences inc	7.41	$ 53.463 Millions	$ 7.218 Millions
Lakewood-Amedex Biotherapeutics Inc.	7.29	$ 4.585 Millions	$ 0.629 Millions
Aspire Biopharma Holdings Inc	7.22	$ 12.167 Millions	$ 1.686 Millions

Date modified: 2026-09-26T07:38:36+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.